A breakthrough discovery offers a promising strategy to overcome resistance in cancer treatments. Researchers have identified a small molecule, UNI418, that disrupts the DNA repair machinery within cancer cells, making them vulnerable again to standard therapies like PARP inhibitors.
This finding addresses one of oncology’s most persistent challenges: drug resistance. Many tumors eventually adapt to treatments by restoring their ability to repair damaged DNA, rendering drugs ineffective. By targeting the stability of repair proteins rather than genetic mutations, this new approach could extend the life and efficacy of existing cancer therapies.
The Mechanism: Breaking Down Defense Systems
Cancer cells survive by efficiently repairing DNA damage, often using a high-accuracy process called homologous recombination. Key proteins in this process include RAD51 and CHK1. While drugs known as PARP inhibitors block one pathway of repair, forcing cells to rely on homologous recombination, many tumors eventually upregulate these repair proteins to resist treatment.
A research team led by Kyungjae Myung at the Institute for Basic Science (IBS) in South Korea, in collaboration with Joo-Yong Lee from Chungnam University, discovered that they could disrupt this defense not by altering genes, but by destabilizing the proteins themselves.
The team identified UNI418, a molecule that triggers the cellular destruction of RAD51 and CHK1. When these proteins are broken down, cancer cells lose their ability to fix DNA breaks efficiently, effectively creating a state of repair deficiency even in resistant tumors.
How UNI418 Works: Metabolism Meets DNA Repair
The study reveals a previously unknown link between cellular metabolism and DNA repair regulation. Here is the step-by-step process:
- Interference with Signaling: UNI418 interferes with a metabolic pathway involving inositol phosphates, specifically lowering levels of a molecule called IP6.
- Removing the Brakes: Under normal conditions, IP6 suppresses the activity of Cul4A, a component of the ubiquitin ligase complex responsible for marking proteins for destruction.
- Activation of Degradation: When IP6 levels drop due to UNI418, the suppression on Cul4A is lifted.
- Targeted Destruction: Cul4A, along with its adaptor protein WDR5, targets DNA repair proteins like RAD51 for degradation.
“We identified a mechanism in which key DNA repair proteins are actively degraded inside the cell. This provides a new way to regulate homologous recombination beyond genetic mutations,” explained co-corresponding author Professor Joo-Yong Lee.
Restoring Sensitivity to Treatment
The clinical potential of this discovery lies in its ability to re-sensitize resistant tumors. In laboratory experiments, UNI418 restored the effectiveness of PARP inhibitors in cancer cells that had previously become resistant.
The researchers tested this combination in animal models using tumor xenografts. The results were significant:
* Reduced Tumor Growth: UNI418 alone slowed tumor progression.
* Enhanced Combination Therapy: When combined with Olaparib (a common PARP inhibitor), the treatment significantly reduced tumor growth, even in models designed to mimic drug-resistant cancers.
Co-corresponding author Kyungjae Myung noted, “By weakening the DNA repair system, we can re-sensitize tumors that have become resistant to existing therapies. This suggests a new strategy for expanding the effectiveness of PARP inhibitors.”
Implications for Future Cancer Therapy
This study shifts the focus from genetic targeting to protein stability as a therapeutic lever. It demonstrates that even after cancer cells develop resistance, they remain dependent on functional DNA repair systems. By destabilizing these systems through metabolic interference, doctors may be able to overcome resistance without developing entirely new classes of drugs.
While UNI418 is still in early stages and requires further development, the mechanism identified provides a strong foundation for future combination therapies. The findings, published in Nature Communications, highlight a novel intersection between metabolism and genome stability, opening new avenues for treating aggressive, drug-resistant cancers.
